{
    "organizations": [],
    "uuid": "7d9f77f08fbc04e539bc915ee6232b16129375fc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novavax-says-topline-efficacy-data/brief-novavax-says-topline-efficacy-data-from-prepare-phase-3-clinical-trial-expected-in-q1-of-2019-idUSASC0A00Y",
    "ord_in_thread": 0,
    "title": "Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) - Novavax Inc:\n* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE\n* NOVAVAX INC - TOPLINE EFFICACY DATA FROM PREPARE PHASE 3 CLINICAL TRIAL EXPECTED IN Q1 OF 2019 Source text for Eikon:\nOur ",
    "published": "2018-05-07T19:14:00.000+03:00",
    "crawled": "2018-05-08T16:52:15.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novavax",
        "inc",
        "novavax",
        "reach",
        "significant",
        "enrollment",
        "milestone",
        "prepare",
        "tm",
        "phase",
        "trial",
        "rsv",
        "f",
        "vaccine",
        "novavax",
        "inc",
        "topline",
        "efficacy",
        "data",
        "prepare",
        "phase",
        "clinical",
        "trial",
        "expected",
        "q1",
        "source",
        "text",
        "eikon"
    ]
}